AIMM Therapeutics’ Partner MedImmune Starts Clinical Studies with RSV Antibody

04-Jul-2014 - Netherlands

AIMM Therapeutics announced that its partner MedImmune, LLC has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.  MEDI8897 originated from AIMM’s D25 antibody. Under the terms of their partnering agreement, AIMM will receive a non-disclosed milestone payment from MedImmune.

D25 was developed from immortalized B cells of an individual exposed to RSV utilizing AIMM’s proprietary antibody technology platform. Preclinical studies have shown that D25 neutralizes RSV with high efficiency by recognizing a unique epitope on the prefusion structure of the F protein expressed on the virus coat.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance